The article explores the potential of AI in drug discovery. Pharmaceutical companies claim that AI can reduce the time required for drug discovery, but these claims need to be independently verified and supported by clinical trial results. The drug discovery process is fraught with uncertainties, and even if AI expedites the preclinical testing phase, the majority of candidate drugs may still fail in later stages. The industry and academia need to collaborate for mutual benefit to determine the best ways to utilize AI.